ApplyBlast uses AI to match you with the right jobs, tailor your resume and cover letter, and apply automatically so you can land your dream job faster.

Features

Auto Apply Resume Optimizer Cover Letter Optimizer Interview Prep

Company

Social Media

Need Help?

team@applyblast.com

Senior Director, RNAi Discovery at Pliant Therapeutics, Inc. - ApplyBlast

Senior Director, RNAi Discovery

Pliant Therapeutics, Inc.

12 hours ago

South San Francisco, California, United States

Hybrid

Full Time

Director

0 applicants

View Job Listing

Apply to 100+ jobs

About this role

Pliant is seeking a Senior Director, RNAi Discovery to build and lead the siRNA discovery engine, owning the end-to-end discovery strategy from bioinformatic design and chemistry optimization to in vivo evaluation and CMC hand-off. This hands-on leadership role emphasizes RNAi design, in vitro screening organization, and cross-functional collaboration to deliver high-quality siRNA development candidates. The position requires a hybrid work schedule with three days per week at the South San Francisco office.

Responsibilities

Define and execute siRNA discovery strategy from target nomination through development candidate selection
Lead bioinformatic design of siRNA libraries and off-target assessment to prioritize sequences
Build and lead in vitro screening organization including cell line selection and assay development

Skills

Qualifications

PhD in molecular biologyPhD in biochemistryPhD in chemistryPhD in computational biology

About Pliant Therapeutics, Inc.

pliantrx.com

Headquarters

South San Francisco, California, United States

Company Size

51-200 employees

Founded

2015

View Profile

Pliant Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of integrin-based therapies. The company leverages its proprietary discovery platform to advance tissue-specific integrin programs targeting a range of diseases, including fibrotic conditions and oncology. Pliant's pipeline includes drug candidates such as PLN-101095 in oncology, with a broader mission to unlock safer and more effective therapies for patients through targeted integrin biology.